RNA Therapeutics Platform
A proprietary platform that integrates multiple gene editing and regulatory components into a single, deliverable RNA molecule — paired with large-fragment delivery systems engineered to overcome the limits of conventional genetic medicine.
Platform
Traditional approaches fragment complexity across multiple delivery vectors and editing systems. Our platform unifies them into a single molecule.
A single IVT RNA encoding all required functional components for coordinated therapeutic action.
A delivery system purpose-built for next-generation RNA therapeutics.
Process
Multiple functional elements are designed within a single RNA construct, enabling coordinated multi-component activity from one molecule.
Proprietary LNP systems transport large RNA payloads into target tissues with high efficiency and cell-type specificity.
Intracellular processing releases independent modules, enabling coordinated biological function from a single delivery event.
Capabilities
Three core modalities, unified within a single platform architecture.
Epigenetic Editing
Programmable, non-permanent control of gene expression without altering the underlying DNA sequence.
Genome Editing
Approaches toward sequence integration beyond single-base editing, with a focus on defined genomic loci relevant to cell engineering.
Protein Replacement
Direct expression of functional proteins via high-expression IVT RNA constructs, enabling therapeutic protein delivery beyond the limits of AAV.
Validation
Our platform is built not only for innovation — but for translatability. Every component is designed with clinical development in mind.
Successfully delivered large RNA constructs exceeding conventional payload limits
Demonstrated coordinated multi-component expression from a single transcript
Enhanced delivery performance compared to conventional transfection systems
Applications
Designed for therapeutic challenges that cannot be solved with single-edit approaches.
Precision hepatic gene modulation for chronic conditions with high unmet need.
Multi-component strategies for diseases beyond the reach of single-edit tools.
Epigenetic reprogramming and multi-target intervention in a single therapy.
We collaborate with leading biopharma and research organizations to unlock new therapeutic possibilities — from multi-component genetic engineering to large payload delivery and strategies beyond conventional CRISPR.
Company
Astral Genetics is advancing a new class of RNA therapeutics designed to address the most challenging diseases — where precision, scale, and coordination are essential. We combine innovative molecular design with next-generation delivery systems to transform genetic medicine from fragmented solutions into unified platforms.
